|
|
Article: Kyodo News International, Tokyo, Business Briefs Column.
- Article from:
- Knight Ridder/Tribune Business News
- Article date:
- July 31, 2003
CopyrightCOPYRIGHT 2003 Knight-Ridder/Tribune Business News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Kyodo News International, Tokyo Knight Ridder/Tribune Business News
Jul. 31--JAPAN TOBACCO INC. OBTAINS SALES RIGHTS FOR GILEAD SCIENCES' ANTI-HIV DRUGS: TOKYO--Japan Tobacco Inc. (JT) said Thursday it has signed a contract with Gilead Sciences Inc. allowing it exclusive sales rights in Japan of the U.S. pharmaceutical firm's anti-HIV drugs.
The contract concerns three types of drug -- VireadR, approved for the U.S. and European markets in October 2001 and July 2002 respectively, Emtriva(TM) approved for the U.S. market on July 2 this year, and a combination drug of the two which Gilead is developing at present.
JT will soon apply to the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Kyodo News International, Tokyo, business ...
Knight Ridder/Tribune Business News;
August 5, 2004 ;
700+ words
...Kyodo News International, Tokyo Knight Ridder/Tribune ... place, it said. To see more of Kyodo News International, go to http://www.kyodonews.com (c) 2004, Kyodo News International, Tokyo. Distributed by Knight ...
|
|